Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17210661 | 0.84 | MEN1 (0.39) | MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL28606840 | 0.77 | ALDH1A1 (0.43) | HDAC8KMT2ACYP3A4MAPT | |
| SCHEMBL26105458 | 0.77 | ALDH1A1 (0.43) | HDAC8KMT2ACYP3A4MAPT | |
| SCHEMBL25898561 | 0.77 | HDAC8 (0.42) | CYP19A1USP2RAB9AHDAC8KIF11 | |
| SCHEMBL127044 | 0.77 | ALDH1A1 (0.43) | HDAC8KMT2ACYP3A4MAPT | |
| SCHEMBL23747179 | 0.77 | HDAC8 (0.42) | CYP19A1USP2RAB9AHDAC8KIF11 | |
| SCHEMBL17974815 | 0.77 | CYP19A1 (0.39) | CYP19A1USP2RAB9AKIF11MEN1 | |
| SCHEMBL1614645 | 0.76 | CYP3A4 (0.47) | CYP19A1CYP3A4LMNA | |
| SCHEMBL15763664 | 0.76 | TSHR (0.48) | CYP19A1RAB9AMEN1KMT2ACYP3A4 | |
| SCHEMBL186944 | 0.74 | RAB9A (0.41) | CYP19A1USP2RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836104-A | Blue light induced method for hydrogen trifluoromethyl of alkynyl compound | 湖南大学 | 2023-10-03 | — | — | CN | disclosed |
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| EP-2736330-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | CYP19A1 597/4885USP2 3862/4885RAB9A 580/4885 |
| US-20140315881-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | CYP19A1 410/4885USP2 3636/4885RAB9A 2352/4885 |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | CYP19A1 2395/4885USP2 2317/4885RAB9A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.